Envestnet Asset Management Inc. Sells 41,369 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Envestnet Asset Management Inc. decreased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 14.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 244,234 shares of the medical research company's stock after selling 41,369 shares during the quarter. Envestnet Asset Management Inc. owned approximately 0.48% of Charles River Laboratories International worth $45,086,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Norges Bank bought a new stake in Charles River Laboratories International during the 4th quarter worth approximately $98,886,000. Wellington Management Group LLP grew its stake in shares of Charles River Laboratories International by 9.0% during the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock valued at $752,508,000 after buying an additional 335,658 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Charles River Laboratories International in the 4th quarter worth approximately $42,776,000. Cooke & Bieler LP lifted its position in Charles River Laboratories International by 42.1% in the fourth quarter. Cooke & Bieler LP now owns 426,767 shares of the medical research company's stock valued at $78,781,000 after purchasing an additional 126,372 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of Charles River Laboratories International by 21.6% during the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock valued at $95,086,000 after purchasing an additional 85,759 shares during the period. Hedge funds and other institutional investors own 98.91% of the company's stock.

Analyst Ratings Changes

CRL has been the topic of a number of research analyst reports. UBS Group restated a "neutral" rating and set a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Mizuho decreased their target price on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a report on Wednesday, April 9th. Citigroup upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and lifted their price target for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. JPMorgan Chase & Co. decreased their price objective on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. Finally, Robert W. Baird cut their target price on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a research note on Thursday, February 20th. One research analyst has rated the stock with a sell rating and sixteen have given a hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $182.00.

Insiders Place Their Bets

In related news, CEO James C. Foster bought 6,075 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were bought at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the transaction, the chief executive officer now owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the sale, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Stock Performance

Shares of CRL traded down $0.96 during mid-day trading on Wednesday, hitting $104.96. 194,005 shares of the company traded hands, compared to its average volume of 1,473,296. The stock has a market cap of $5.16 billion, a price-to-earnings ratio of 700.34, a P/E/G ratio of 4.54 and a beta of 1.45. The stock has a 50-day moving average price of $154.31 and a two-hundred day moving average price of $175.73. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $254.15. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company's quarterly revenue was down 1.1% compared to the same quarter last year. During the same period in the previous year, the business earned $2.46 EPS. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).